Please provide your email address to receive an email when new articles are posted on . Adults with overweight or obesity plus preexisting CVD had a reduction in CV event risk with semaglutide in ...

The use of semaglutide for non-diabetic obese patients with cardiovascular disease was first reported to be associated with significant benefit in the SELECT trial, where major adverse cardiovascular ...

Semaglutide is at least as effective at preventing heart attacks and other cardiac events as well as death in people with impaired kidney function as it is in those with normal kidney function The ...

Among patients who have obesity-related heart failure with preserved ejection fraction (HFpEF), once-weekly semaglutide 2.4 mg (Wegovy; Novo Nordisk) induces greater weight loss in women than in men ...

In a recent study published in Nature Medicine, researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction (HFpEF). Study ...

Coverage from a symposium, “Weight loss as a new therapeutic target in HFpEF: dawn of a new era?” that took place August 27 during the European Society of Cardiology 2023 Congress. A new study showing ...

Patients with type 2 diabetes and a baseline HbA1c greater than 7.0% experienced greater cardiovascular benefits while using oral semaglutide. Oral semaglutide elicits more pronounced cardiovascular ...

Weight management medications are transforming the landscape of obesity treatment, with semaglutide emerging as a groundbreaking solution for individuals struggling with weight loss. As demand surges ...

A detailed analysis in the Canadian Journal of Cardiology of the cost-effectiveness of semaglutide shows that with price reductions, it could meet the benchmark for healthcare value, urging ...

Key market opportunities for liraglutide and semaglutide include their growing role in diabetes and obesity treatment due to ...

The semaglutide market offers major opportunities in expanding obesity treatments and oral formulations, capitalizing on ...